香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示， 概不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 HUTCHMED (China) Limited 和黃醫藥（中國）有限公司 （於開曼群島註冊成立的有限公司） （股份代號：13） 和黃醫藥公佈 2023 年中期業績及最新業務進展 戰略方向得以有力執行，在規劃增長道路的同時實現近期價值，以武田製藥的全球合作為例證 收入增長164%（按固定匯率計算為173%）至5.33億美元，和黃醫藥的淨收益為1.69億美元 （其中包括武田製藥支付的首付款中已確認的2.59 億美元） 公司將於今天中國香港時間晚上8時正/ 英國夏令時間下午1時正/ 美國東部夏令時間上午8時正 舉行中期業績電話會議及網絡直播 公司將於今年第四季度舉辦資本市場日（Capital Markets Day） 和黃醫藥（中國）有限公司（簡稱「和黃醫藥」、「本公司」或「我們」）是一家處於商業化階段的創新型生物醫 藥公司，今日公佈截至 2023 年 6 月 30 日止六個月的未經審核財務業績以及提供關鍵臨 ...

Exhibit 99.1 HUTCHMED Reports 2023 Interim Results and Provides Business Updates Strong execution on strategic direction, delivering near-term value while charting a path for growth, exemplified by global partnership with Takeda Revenue grew 164% (173% CER) to US$533 million, with net income to HUTCHMED of US$169 million (which include US$259 million of the upfront recognized from Takeda) Company to Host Interim Results Call & Webcast Today at 8 p.m. HKT / 1 p.m. BST / 8 a.m. EDT Company to host a Capital M ...

Financial Performance - Total revenue for 2022 increased by 20% to $426.4 million, driven by the commercialization of three self-developed oncology drugs in China[14]. - Other business revenue grew by 11% to $262.6 million in 2022, with Shanghai Hengrui's non-consolidated joint venture revenue also increasing by 11% to $370.6 million[27]. - The company reported a net loss attributable to the company of $360.8 million in 2022, compared to a net loss of $194.6 million in 2021, resulting in a loss per share of $0.43[36]. - The company’s total revenue for the tumor/immunology business was $296.6 million in 2022, compared to $(306.3) million in 2021[106]. - The revenue from prescription drugs was $237.3 million in 2022, a 16% increase from $204.1 million in 2021[107]. - The company’s revenue from Shanghai Huanong Pharmaceutical was $370.6 million in 2022, an 11% increase from $332.6 million in 2021[107]. Oncology/Immunology Business - Revenue from oncology/immunology business grew by 37% (41% at constant exchange rates), aligning with financial guidance[7]. - Oncology/immunology business revenue grew by 37% to $163.8 million, with significant contributions from key products[15]. - Fruquintinib (爱优特) sales increased by 32% to $93.5 million, reflecting a growing market share, especially in second and third-tier cities[14]. - Surufatinib (苏泰达) sales surged by 178% to $32.3 million, benefiting from its inclusion in the national medical insurance catalog[14]. - Savolitinib (沃瑞沙) sales rose by 159% to $41.2 million, recognized as China's first selective MET inhibitor[14]. Clinical Trials and Drug Development - The FRESCO-2 Phase III international study for fruquintinib in treating refractory metastatic colorectal cancer achieved its primary endpoint, with rolling submission for new drug application to the US FDA initiated[7]. - Over 15 registration/registration intention studies involving six products are currently ongoing[7]. - The FRUTIGA Phase III study for fruquintinib in gastric cancer reached the PFS endpoint, with supplementary application for new indication underway[7]. - The company has advanced 13 oncology candidate drugs into clinical trials in China, with four also undergoing clinical development in the US and Europe[40]. - The company is developing six early-stage oncology candidates, including HMPL-306, a selective oral IDH1/2 dual inhibitor, and HMPL-760, a third-generation oral BTK inhibitor[23]. Strategic Partnerships and Collaborations - The company successfully entered into a licensing agreement with Takeda Pharmaceuticals, marking a significant strategic step[8]. - The collaboration with Takeda Pharmaceuticals for furmonertinib includes a potential total of up to $1.13 billion, with an initial payment of $400 million and up to $730 million in milestone payments[25]. - The company has established a partnership with Eli Lilly for the marketing and promotion of Aiyoute in China, receiving 70-80% of the production revenue, service fees, and royalties from sales[41]. Research and Development - R&D expenses increased to $386.9 million in 2022 from $299.1 million in 2021, primarily due to the expansion of innovative oncology drug development[35]. - The company plans to continue early development projects for candidates with global differentiation advantages, including sovleplenib, in the US, Europe, and Japan[11]. - The company is investing $50 million in R&D for new technologies and product development in the upcoming year[144]. Market Expansion and Future Outlook - A new strategic focus was announced in November to accelerate the establishment of a sustainable and profitable business[10]. - Future outlook includes a projected revenue growth of 15% for the next fiscal year, driven by new product launches and market expansion strategies[144]. - Plans for market expansion include entering three new international markets by the end of 2024, targeting a 20% increase in market share[144]. Financial Position and Cash Flow - As of December 31, 2022, cash and cash equivalents totaled $631 million, down from $1.011 billion in 2021[34]. - The company reported a net cash outflow from financing activities of $82.8 million in 2022, compared to a net cash inflow of $650 million in 2021[34]. - The total assets decreased to $1.029 billion as of December 31, 2022, from $1.373 billion in 2021[37]. Corporate Governance and Management - The company has seen changes in its board composition, with several directors transitioning to new roles or resigning from previous positions[155]. - The company’s board members have extensive experience in the pharmaceutical and financial sectors, enhancing its governance and strategic direction[154][156]. - The company emphasizes the importance of high-quality human resources to maintain market leadership and offers competitive salaries and benefits[1]. Sustainability and Social Responsibility - The company has established a comprehensive sustainability governance framework and set 11 sustainability goals and indicators[29]. - The board has approved a new sustainability strategy aimed at reducing carbon emissions by 40% by 2030[144]. - The group donated approximately $2.7 million to charitable organizations in the year ended December 31, 2022, compared to about $1.89 million in 2021, representing an increase of approximately 42%[176].

Exhibit 99.1 Press Release HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer — NDA supported by data from global Phase III FRESCO-2 study in the U.S., Europe, Japan and Australia along with data from Phase III FRESCO study conducted in China — — FRESCO-2 showed fruquintinib treatment reduced the risk of death by 34% in refractory metastatic colorectal cancer (0.66 HR), consistent with the 35% reduction in the risk of death ...

HUTCHMED (China) Limited (NASDAQ:HCM) Q4 2022 Earnings Conference Call February 28, 2023 8:00 AM ET Company Participants Mark Lee - SVP Corporate Finance and Development Weiguo Su - CEO and Chief Scientific Officer Hong Chen - Chief Commercial Officer Johnny Cheng - CFO Karen Atkin - COO Mike Shi - Chief Medical Officer and Head of R&D Conference Call Participants Kelly Shi - Jefferies Louise Chen - Cantor Alec Stranahan - Bank of America Merrill Lynch Yang Huang - Credit Suisse Mike Mitchell - Panmure Gor ...

Exhibit 99.1 HUTCHMED Reports 2022 Full Year Results and Provides Business Updates Landmark licensing deal with Takeda for fruquintinib outside of China, bringing HUTCHMED up to US$1.13 billion, plus royalties, and demonstrating execution of the new global strategy Record Full Year 2022 oncology/immunology revenues driven by significant increase in China in-market sales of ELUNATE, SULANDA and ORPATHYSalongside clinical and strategic progress Company to Host Annual Results Call & Webcast Today at 9 p.m. HKT ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark one) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR Date of event requiring this shell comp ...